Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25

Coline Montégut; Claire Falandry; Saverio Cinieri; Claire Cropet; Laure Montané; Frédérique Rousseau; Florence Joly; Malak Moubarak; Anna Maria Mosconi; Eva M. Guerra-Alia; Christian Schauer; Hiroyuki Fujiwara; Ignace Vergote; Gabriella Parma; Gabriel Lindahl; Amélie Anota; Ulrich Canzler; Frederik Marmé; Eric Pujade‐Lauraine; Isabelle Ray‐Coquard; Renaud Sabatier

doi:10.1093/oncolo/oyae322

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among older patients in PAOLA-1, olaparib plus bevacizumab had a manageable safety profile and no adverse impact on QoL. Additional data are required to confirm these results in more vulnerable patients.(ClinicalTrials.gov Identifier: NCT02477644).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Montégut et al. (2024) studied this question.

synapsesocial.com/papers/69d944b6f20ef26330684636 https://doi.org/10.1093/oncolo/oyae322

View Full Paper

Ask AI

Bookmark

Share

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25

Ask about this paper

Abstract

Discussion

Cite This Study

Safety and quality of life with maintenance olaparib plus bevacizumab in older patients with ovarian cancer: subgroup analysis of PAOLA‑1/ENGOT-ov25

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading